The global overactive bladder treatment market is estimated to grow at a CAGR of nearly 3.5% during the forecast period. The major factors contributing to the growth of the market include a significant rise in geriatric population and rising incidences of Parkinson’s disease and spinal cord injuries. As per the data published by the National Spinal Cord Injury Statistical Center, as of 2019, in the US, the annual incidence of spinal cord injury is approximately 54 cases per one million people, or nearly 17,730 new spinal cord injury cases each year. As of 2019, the estimated number of individuals suffering from spinal cord injury in the US is nearly 291,000.

Nearly 78% of new incidences were reported among males. Injury in the spinal cord may interrupt communication between the spinal cord nerves that control the functioning of bowel and bladder, causing incontinence. This leads to the dysfunction of bladder or bowel which is referred to as neurogenic bladder. Therefore, bladder relaxing medications including anticholinergic for reflexive bladder and oxybutynin (Ditropan) is commonly prescribed by the physicians that are familiar with spinal cord injury.

Anticholinergic medications have a primary side-effect of dry mouth. Botulinum toxin A (Botox) may be a substitute to anticholinergics which is the US FDA approved for the treatment of detrusor overactivity among patients with spinal cord injury and multiple sclerosis. The major benefit of Botox is that it is utilized focally in the bladder and thereby eliminates systemic side-effects, including dry mouth. Therefore, the rising incidences of spinal cord injury are expected to drive the demand for bladder treatment and thereby encouraging the adoption of medications that are used for overactive bladder cancer treatment.

Market Segmentation

The global overactive bladder treatment market is segmented based on therapy and application. Based on therapy, the market is classified into anticholinergics, intravesical instillation, mirabegron, neurostimulation, and others. Based on application, neurogenic overactive bladder and idiopathic overactive bladder. 

Idiopathic overactive bladder is anticipated to hold significant share in the application segment

Idiopathic overactive bladder is expected to contribute significantly in the market growth owing to the increasing prevalence of urinary incontinence coupled with the rising geriatric population. As per the World Health Organization (WHO), the prevalence of urinary incontinence ranges from 9.9% to 36.1% and is twice as high in older women as in older men. This results in the demand for idiopathic overactive bladder treatment. Several medications are recommended for overactive bladder treatment. These medications use along with behavioral therapies has demonstrated to augment the accomplishment rate for overactive bladder treatment.

Anticholinergics are the most common medications used to reduce the overactivity of the bladder muscle. These medications may have certain side effects, such as blurry vision, dry mouth, and constipation. Estrogen, either vaginal or oral, may be useful in combination with other treatments for urinary incontinence among postmenopausal women. Other novel overactive bladder therapies are in trial phases and some therapies are rarely used in special cases. For instance, botulinum toxin injection (Botox) into the bladder muscle may be useful in some urge incontinence patients who have not responded to other conventional treatments. 

Global Overactive Bladder Treatment Market Share by Application, 2018 (%)

Regional Outlook

The global overactive bladder treatment market is segmented into four major regions, including North America, Europe, Asia-Pacific, and Rest of the World (RoW). North America is anticipated to hold a significant share in the market owing to the increasing prevalence of urinary incontinence coupled with the increasing prevalence of geriatric population in the region. In addition, the increasing prevalence of Parkinson’s disease and spinal cord injuries are further driving the demand for overactive bladder treatment in the region. As per the Parkinson’s Foundation, nearly 60,000 Americans are diagnosed with Parkinson’s disease each year. Parkinson’s disease increases with age, however, an estimated 4% of people with Parkinson’s disease are diagnosed before age 50. Bladder and bowel disorders are common among patients with Parkinson’s disease. This leads to the increasing demand for overactive bladder treatment in the region.

Global Overactive Bladder Treatment Market Growth, by Region 2019-2025

Market Players Outlook

The major players operating in the market include Astellas Pharma Inc., Pfizer Inc., Medtronic plc, Allergan plc, and Mylan N.V. These companies are significantly focusing on new product launches to gain significant share in the market. Several new approvals for drugs and devices have been reported for the treatment of overactive bladder. For instance, in January 2020, Medtronic plc received CE Mark for its InterStim SureScan MRI leads and InterStim Micro neurostimulator. InterStim Micro is a rechargeable device that offers sacral neuromodulation (SNM) therapy for the treatment of non-obstructive urinary retention, overactive bladder, and fecal incontinence. The device is 80% smaller as compared to the current recharge-free InterStim II neurostimulator and might decrease the requirement for battery replacement surgeries owing to its 15 years life.  This launch will enable the company to increase the access of its SNM therapy for European patients. 

The Report Covers

• Market value data analysis of 2018 and forecast to 2025.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global overactive bladder treatment market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.